Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BlackRock TCP Capital Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while BlackRock TCP Capital Corp trades at $3.9 (market cap $327.64M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 90.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TCPC | |
|---|---|---|
Market Cap | $29.60B | $327.64M |
Sector | Health | Financials |
52-Week High | $491.22 | $7.26 |
52-Week Low | $205.48 | $3.13 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 19.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
TCPC trades at $4.00, up 1.52% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a low P/B of 0.59 suggesting potential undervaluation amid financial challenges.
The outlook is mixed: strategic actions and dividend yield near 8.5% offer value, but persistent losses, class action lawsuits, and high P/S ratio pose significant risks. Analyst consensus is cautious with more holds than buys, reflecting uncertainty over the company's turnaround efforts and profitability path.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
